Brief: Mabion Signs LoI With Oddifact On Use Of MabionCD20 Drug For Orphan Diseases
08/05/2026 06:49
May 8 (Reuters) - Mabion SA MABP.WA: SAID ON THURSDAY THAT THEY SIGNED A LETTER OF INTENT WITH FRENCH ODDIFACT SAS TO COOPERATE ON THE USE OF DRUG MABICONCD20 IN THE AREA OF ORPHAN DISEASES THE AIM IS TO DEVELOP AND REGISTER THE MABIONCD20 DRUG SAYS PARTIES AIM TO SIGN A BINDING COOPERATION AGREEMENT BY END-2026 Source text for Workspace: nEM67wXQsa Further company coverage: MABP.WA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects